Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 16, 2021 07:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces Completion of Enrollment in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

Top-line data expected by end of Q1 2021 DELRAY BEACH, Fla., March 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage...
January 26, 2021 07:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients

DELRAY BEACH, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
November 17, 2020 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients

Potential to add additional study arm utilizing immediate release capsules Trial objectives, endpoints and statistical analysis to remain the same DELRAY BEACH, Fla., Nov. 17, 2020 (GLOBE...
August 13, 2020 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

First three patients enrolled in dose escalation trial using delayed-release enteric capsulesTopline data expected in 1H 2021 NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc....
July 22, 2020 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis – with First Patient Screened and Three Clinical Trial Sites Activated

Three OPTION 2 clinical trial sites activated in the U.S.Topline data expected in Q1 2021 NEW YORK, July 22, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the...